Scott A Sands, Jinny Collet, Laura K Gell, Nicole Calianese, Lauren B Hess, Daniel Vena, Ali Azarbarzin, Suzanne M Bertisch, Shane Landry, Luke Thomson, Simon A Joosten, Garun S Hamilton, Bradley A Edwards
RATIONALE: Acetazolamide and atomoxetine-plus-oxybutynin ('AtoOxy') can improve obstructive sleep apnoea (OSA) by stabilising ventilatory control and improving dilator muscle responsiveness respectively. Given the different pathophysiological mechanisms targeted by each intervention, we tested whether AtoOxy-plus-acetazolamide would be more efficacious than AtoOxy alone. METHODS: In a multicentre randomised crossover trial, 19 patients with moderate-to-severe OSA received AtoOxy (80/5 mg), acetazolamide (500 mg), combined AtoOxy-plus-acetazolamide or placebo at bedtime for three nights (half doses on first night) with a 4-day washout between conditions...
January 29, 2024: Thorax